Gregory J. Mazzola

GSK R&D
Senior Director, Medicine & Process Delivery
Greg holds a B.S. in Biology from the University of Vermont and an M.S. in Microbiology from Thomas Jefferson University. He has over 25 years of experience in biopharmaceutical process development, tech transfer, and validation for monoclonal antibodies, ADCs, unique protein therapeutics, and small molecules. Greg has worked at GSK for 22 years, 14 of which were in the Biopharmaceutical Process Development organization. For the past 8 years, Greg has led the overall CMC program for multiple products as a Medicine and Process Delivery Leader in GSK R&D. MPD Leaders hold single-point accountability for the CMC program and lead matrix teams from FTIH through post-launch activities. This functional role spans process and product development, quality, analytical, CMC regulatory, manufacturing, and supply chain logistics. Greg has led the CMC program for several products indicated for terminal illnesses creating strategies for accelerating regulatory pathways to bring medicines to patients as quickly as possible.

Related Articles

Accelerated Pharma Product Development, Registration, Commercialization & Life Cycle
Features
Accelerated Pharma Product Development, Registration, Commercialization & Life Cycle

This article is Part 1 of a two-part series exploring what we can learn from examples of pharmaceutical products being approved using accelerated programs. The series focuses on challenges that chemistry, manufacturing, and control (CMC) development teams may encounter when a project is given accelerated development status. Part 1 introduces key considerations and themes in general terms and...